Skip to main content
. 1999 Oct 25;1999(4):CD003274. doi: 10.1002/14651858.CD003274

Comparison 9. BUD v Placebo: parallel studies, not on oral steroids: all severities.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 FEV1 (% predicted) 7 197 Mean Difference (IV, Fixed, 95% CI) ‐3.65 [‐7.22, ‐0.08]
1.1 Mild 5 129 Mean Difference (IV, Fixed, 95% CI) ‐4.09 [‐8.14, ‐0.03]
1.2 Mild to moderate 2 68 Mean Difference (IV, Fixed, 95% CI) ‐2.17 [‐9.65, 5.31]
1.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FEV1 (litres) 4 103 Mean Difference (IV, Fixed, 95% CI) 0.07 [‐0.25, 0.40]
2.1 Mild 2 47 Mean Difference (IV, Fixed, 95% CI) 0.14 [‐0.27, 0.55]
2.2 Mild to moderate 1 26 Mean Difference (IV, Fixed, 95% CI) ‐0.38 [‐1.08, 0.32]
2.3 Moderate 1 30 Mean Difference (IV, Fixed, 95% CI) 0.41 [‐0.40, 1.22]
2.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in FEV1 (litres) compared to baseline 2 99 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐0.33, ‐0.07]
3.1 Mild 2 99 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐0.33, ‐0.07]
3.2 Mild to moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Morning PEFR (L/min) 2 77 Mean Difference (IV, Fixed, 95% CI) ‐31.22 [‐71.25, 8.80]
4.1 Mild 1 31 Mean Difference (IV, Fixed, 95% CI) ‐28.0 [‐86.82, 30.82]
4.2 Mild to moderate 1 46 Mean Difference (IV, Fixed, 95% CI) ‐34.0 [‐88.62, 20.62]
4.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in morning PEFR (L/min) compared to baseline 6 469 Mean Difference (IV, Fixed, 95% CI) ‐28.92 [‐36.11, ‐21.74]
5.1 Mild 4 259 Mean Difference (IV, Fixed, 95% CI) ‐30.91 [‐39.50, ‐22.32]
5.2 Mild to moderate 2 210 Mean Difference (IV, Fixed, 95% CI) ‐24.28 [‐37.41, ‐11.15]
5.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in evening PEFR (L/min) compared to baseline 6 469 Mean Difference (IV, Fixed, 95% CI) ‐20.64 [‐28.29, ‐13.00]
6.1 Mild 4 259 Mean Difference (IV, Fixed, 95% CI) ‐18.39 [‐27.60, ‐9.19]
6.2 Mild to moderate 2 210 Mean Difference (IV, Fixed, 95% CI) ‐25.65 [‐39.38, ‐11.93]
6.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in daytime use of short‐acting beta2 agonist (puffs/daytime) compared to baseline 5 480 Mean Difference (IV, Fixed, 95% CI) ‐0.43 [‐0.80, ‐0.06]
7.1 Mild 4 311 Mean Difference (IV, Fixed, 95% CI) ‐0.49 [‐0.95, ‐0.04]
7.2 Mild to moderate 1 169 Mean Difference (IV, Fixed, 95% CI) ‐0.32 [‐0.93, 0.29]
7.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in night‐time use of short‐acting beta2 agonist compared to baseline (puffs/night) 3 304 Mean Difference (IV, Fixed, 95% CI) ‐0.71 [‐1.09, ‐0.33]
8.1 Mild 2 133 Mean Difference (IV, Fixed, 95% CI) ‐0.96 [‐1.67, ‐0.24]
8.2 Mild to moderate 1 171 Mean Difference (IV, Fixed, 95% CI) ‐0.61 [‐1.06, ‐0.16]
8.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Methacholine bronchial responsiveness (log 10 values) 3 76 Mean Difference (IV, Fixed, 95% CI) ‐0.04 [‐0.29, 0.21]
9.1 Mild 2 54 Mean Difference (IV, Fixed, 95% CI) ‐0.12 [‐0.48, 0.23]
9.2 Mild to moderate 1 22 Mean Difference (IV, Fixed, 95% CI) 0.04 [‐0.31, 0.39]
9.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Histamine bronchial responsiveness (log 10 values) 2 80 Mean Difference (IV, Fixed, 95% CI) ‐0.40 [‐0.70, ‐0.11]
10.1 Mild 1 31 Mean Difference (IV, Fixed, 95% CI) ‐0.40 [‐0.70, ‐0.10]
10.2 Mild to moderate 1 49 Mean Difference (IV, Fixed, 95% CI) ‐0.53 [‐2.75, 1.69]
10.3 Moderate 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Moderate to severe 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Withdrawal due to asthma exacerbation (No. of patients) 17 910 Risk Ratio (M‐H, Fixed, 95% CI) 0.17 [0.09, 0.33]
11.1 Mild 12 520 Risk Ratio (M‐H, Fixed, 95% CI) 0.32 [0.13, 0.81]
11.2 Mild to moderate 4 366 Risk Ratio (M‐H, Fixed, 95% CI) 0.11 [0.04, 0.28]
11.3 Moderate 1 24 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.4 Moderate to severe 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Requirement for one or more courses of oral steroid for asthma exacerbation (No. of patients) 5 255 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.25 [0.13, 0.48]
12.1 Mild 3 109 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.38 [0.13, 1.13]
12.2 Mild to moderate 2 146 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.20 [0.09, 0.44]
12.3 Moderate 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.4 Moderate to severe 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Oropharyngeal side effects (No. of patients) 5 275 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.53, 1.23]
13.1 Mild 4 159 Risk Ratio (M‐H, Fixed, 95% CI) 1.26 [0.69, 2.31]
13.2 Mild to moderate 1 116 Risk Ratio (M‐H, Fixed, 95% CI) 0.55 [0.30, 1.00]
13.3 Moderate 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 Moderate to severe 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]